A high-performance liquid chromatographic technique for the simultaneous determination of prednisolone and prednisone in human plasma, whole blood, urine, and bound-to-plasma proteins, using betamethasone as internal standard, is presented. Liquid-liquid extraction is used for whole blood samples, and solid phase extraction is used for plasma, urine, and proteins bound to plasma. The accuracy, precision, specificity, linearity, and repeatability meet the requirements of current recommendations in bioanalytical method validation. The method is suitable for high altitude pharmacokinetic studies, in which the quantitation of drugs in those fluids is required. The results from healthy volunteers are presented.
Introduction
P rednisone and prednisolone are widely used synthetic cort i c o st e roids in inflammatory conditions, neoplastic diseases, asthma, and as immunosuppressive agents. Prednisone is both a pro d ru g and a metabolite of the active drug prednisolone (1, 2) . A number of studies have been published in the literature describing their p h a rmacokinetics (1) (2) (3) (4) , and analytical methods to assay both compounds in plasma and urine have been re p o rted (5-7).
High-altitude pharmacokinetic studies are a new and very i m p o rtant field in pharmacology because short-or long-term e x p o s u re to a high altitude generates a number of physiological changes that may alter the absorption and disposition of drugs in those circumstances. Acute mountain sickness has become a public health problem and has consequences for people who live and work at high altitudes and also in sport medicine and other g roups of interest. Few studies have been published in the literat u re related to high-altitude pharmacokinetics (8) (9) (10) (11) . As physiological changes caused by high-altitude exposure may involve all the pharmacokinetic processes, the appropriate characterization of such changes needs to assay the drug in diff e rent biological fluids. Quantitation of drugs in plasma, whole blood, urine, and bound-to-plasma proteins (plasma proteins) allows the study of the influence of high altitudes on ery t h rocyte binding, excre t i o n rate, and unbound drug fraction, all of which are relevant to the clinical effects of drugs. The high-perf o rmance liquid chro m a t o graphy (HPLC) methods currently available are appropriate for measuring prednisone and prednisolone in plasma and urine, but an HPLC method that is simultaneously appropriate for the four d i ff e rent fluids previously mentioned has not been found in the l i t e r a t u re. The purpose of this work has been to develop and validate an HPLC method that is easy to apply and serves to determine prednisone and prednisolone in humans in diff e re n t biological fluids, as is re q u i red in pharmacokinetic studies.
Experimental

Apparatus
Liquid chromatograph
The HPLC system consisted of a Model L-6200 A, a Model L-7250 LaChrom autosampler, and a programmable L-4250 UV-vis absorbance detector (Merck, Darmstadt, Germany). Data re c o rding was carried out by D7000-HSM software (Merc k ) .
Column
The separation was perf o rmed by Lichro C A RT 250-4 L i c h rospher Si 60 (Merck) column (250-× 4.6-mm i.d., 5-µm particle size) and Lichro C A RT 4-4 Si 60 (5-µm particle size) guard column (Merck).
Analytical sample Preparation of stock solution, internal standard, calibration standard, and quality control samples
Stock solutions of prednisolone and prednisone were pre p a re d in mobile phase (20 µg/mL). Internal standard solutions of betamethasone were pre p a red in mobile phase (20 µg/mL). Ultrasonic was used for several minutes in order to accelerate the dissolution. The nominal plasma concentrations of the calibration standard were 100, 250, 500, 750, 1000, and 1500 ng/mL. The nominal concentrations of the calibration standard in urine, whole blood, and plasma proteins were 100, 250, 500, 750, 1000, 1250, and 1500 ng/mL). Three levels of quality control at 100, 500, and 1500 ng/mL were pre p a red.
Samples Preparation
Procedure to obtain drug bound to plasma proteins A 1-mL sample of plasma was filtered with an YM 50 Centricon filter (Amicon, Bedford, MA) for 25 min at 2500 g; the filtere d (plasma-water) was discarded. The biological matrix obtained was named plasma pro t e i n s .
Extraction procedure for plasma, urine, and plasma proteins
A 100-µL sample of internal standard solution (20 µg/mL) was added to 500 µL of plasma, 100 µL of urine or 500 µL of plasma p roteins prior to solid-phase extraction (SPE). The extraction system consisted of a Lichrolut RP-18 solid-phase column ( M e rck). Methanol, ethyl acetate, and acetonitrile were used for SPE. Sodium hydroxide (0.2N) was used to wash the eluate after SPE. The SPE column was activated with 1 mL methanol and washed with 1 mL of distilled water. The sample was passed slowly t h rough the SPE column and then washed with 1 mL of distilled water for plasma and plasma proteins and 2 mL for urine. The sample was eluted with 3 mL of acetonitrile for plasma and plasma proteins, and with ethyl acetate (9 mL) for urine. In the case of urine, the eluate was washed with 3 mL sodium hydro x i d e (0.2N). The samples were evaporated to dryness under nitro g e n s t ream at 37°C. The residue was reconstituted with 300 µL of mobile phase and vortex mixed for 30 s. The solution was filtere d t h rough a 0.22 µm GVWP Millipore filter (Bedford, MA).
Extraction procedure for whole blood
A 1.5-mL sample of distilled water was added to 500 µL of whole blood and mixed by shaking. A 100-µL sample of internal stand a rd solution (20 µg/mL) was added to the sample prior to the liquid-liquid extraction. Sodium hydroxide and ethyl acetate w e re used for liquid-liquid extraction. Ethyl acetate (9 mL) was added and shaken for 15 min. The sample was centrifuged for 10 min at 1800 g; the organic phase was removed and washed by shaking with 3 mL of 0.2N NaOH. The organic phase was separated and evaporated to dryness under nitrogen stream at 37°C. The residue was reconstituted with 300 µL of mobile phase and v o rtex mixed for 30 s. The solution was filtered through a 0.22-µm GVWP Millipore filter.
Chromatographic conditions
Mobile phase
The The eluate was monitored by UV absorbance at 254 nm. The injection volume was 100 µL.
Defining assay characteristics Specificity
To demonstrate the specificity of the method, blanks of plasma, urine, and whole blood were analyzed. As recommended (12) , plasma, urine, and whole blood samples from at least six diff e re n t s o u rces were used during validation. Each blank sample was tested for interfering substances, mainly endogenous matrix c o m p o n e n t s .
Linearity
For the evaluation of linearity, a linear re g ression model in a s t a n d a rd curve with seven concentrations between 100 ng/mL and 1500 ng/mL and three quality control samples (100 ng/mL, 750 ng/mL, and 1500 ng/mL) was used. In accordance with the Food and Drug Administration's recommendations for evaluation of linearity, a plot of concentration versus signal and the mean relative error (RE) of the interpolated concentration of the quality c o n t rol standards were taken into consideration.
Eq. 1
The following criteria were taken into account to assess linearity: the values for the medium-and high-quality control samples should be within 15% of the actual value, only low quality c o n t rol samples could be within 20%, four to six quality contro l samples fulfilled the same criteria and a correlation coefficient ≥ 0.95 was considered adequate (12) .
Precision and accuracy
Accuracy and precision for the assay were determinated by calculating the interday variation at three concentrations (100, 750, and 1500 ng/mL) in six replicates for plasma and urine, in five re p l icates for whole blood, and in three replicates for plasma pro t e i n s .
P recision was expressed as the coefficient of variation (CV) of the interpolated concentrations. A CV ≤ 15% for medium and high controls and ≤ 20% for low range is acceptable (12) .
Accuracy was expressed as the RE of the interpolated concentration of samples. A RE ≤ 15% for medium and high contro l s , and ≤ 20% for low range is acceptable (12).
Limit of quantitation
The limit of quantitation (LOQ) was determined by re p e a t e d analysis of spiked plasma, urine, whole blood, and plasma pro t e i n samples (n = 6). Precision and accuracy were calculated. Following international recommendations a CV ≤ 20% is acceptable at the LOQ (12) .
Recovery
The assay re c o v e ry for each steroid was determined at thre e concentrations (n = 3). A minimum of 50% of re c o v e ry was used as criteria. The absolute re c o v e ry (AR) was calculated using peak a reas of extracted biological samples (n = 3 at each concentration) and directly injecting solutions of the same concentrations. AR interpolated concentration of s t a n d a rd -nominal concentration nominal concentration RE = × 1 0 0 was calculated using the same matrix as a re f e rence, which was purified before the addition of the standard solutions.
Eq. 2
Stability of the extracted samples After the extraction pro c e d u re, the spiked samples with known concentrations (100, 750, and 1500 ng/mL) were stored for thre e months at -20°C and analyzed using the same HPLC method. Quality control samples were compared with a calibration curv e p re p a red fre s h l y, after 1, 2, and 3 weeks, and 1, 2, and 3 months.
Results
Specificity
F i g u re 1 shows the chromatograms of a blank individual volunteer whole blood sample (A), a blank whole blood sample spiked with prednisone, prednisolone, and betamethasone (B), and a whole blood sample of a volunteer after an oral administration of 80 mg of prednisolone (C). The chromatograms demonstrated that the compounds of interest could be detected separately and without interf e rence with endogenous compounds. C h romatograms of plasma, urine, and plasma proteins showed v e ry similar behavior, with fewer signals from the biological matrix than whole blood. Total time of analysis was 20 min for all the samples. Table I gives the slopes, intercept, and correlation coeff i c i e n t s for the four biological matrices. Correlation coefficients for plasma, urine, and plasma proteins were 0.99 and 0.97 for whole blood. Table II shows the values obtained during a 6-day validation for repeatability and accuracy for plasma. The CV for each biological fluid ranged from: 2.1% to 3.5% for prednisone and 3.5% to 4.6% for prednisolone in plasma; from 1.1% to 5.7% for pre d n i s o n e and 3.8% to 8.9% for prednisolone in urine; from 4.3% to 14.6% for prednisone and 4.7% to 13.5% for prednisolone in whole blood; and from 4.3% to 6.7% for prednisone and 2.8% to 6.9% for prednisolone in plasma pro t e i n s .
Linearity
Precision and accuracy
LOQ
The LOQ determined by repeated analysis was 100 ng/mL for p rednisolone for each biological fluid. For prednisolone the pre c ision at the LOQ was determined as CV = 8.3% and for pre d n i s o n e 5.3%; the mean RE was 13.0% for prednisolone and 17.0% for p rednisone in plasma. The CV was 6.0% for prednisolone and 4.3% for prednisone; the mean RE was 17.7% for pre d n i s o l o n e and 18.0% for prednisone in urine. For whole blood, the CV was 11.7% for prednisolone and 10.8% for prednisone; the mean RE Table I 
A B C
was 19.4% for prednisolone and 18.2% for prednisone. The CV was 6.3% for prednisolone and 6.0% for prednisone, the mean RE was 16.6% for prednisolone and 15.2% for prednisone in plasma p ro t e i n .
Recovery
The absolute recoveries of prednisolone, prednisone, and betamethasone are listed in Table III . The CV ranged from 0.9% to 4.3% for plasma, 3.0% to 6.9% for urine, 2.3% to 4.5% for plasma p roteins, and 5.6% to 11.3% for whole blood.
Stability
The samples were stable for at least 3 months.
Volunteer samples F i g u re 2 shows the concentration time profiles for plasma and whole blood, and Figure 3 shows the amount of prednisolone and p rednisone excreted in urine, both from a healthy volunteer after the administration of 80 mg of prednisolone (Prelone, Asta Medica, Brasil) 2 0 4 
Discussion
The method for the simultaneous determination of pre dnisolone and prednisone in plasma, whole blood, urine, and plasma proteins in healthy volunteers following oral administration of prednisolone is shown to be eff i c i e n t .
Plasma protein binding to some drugs has been re p o rted to be a l t e red in subjects exposed to high altitudes (8) . Data on the binding of prednisolone and prednisone to plasma proteins are i m p o rtant to better understand the pharmacokinetics of these d rugs. Prednisolone and prednisone have a 90% rate of binding to protein (13) . For this reason, it was necessary to develop a method to measure the amount of drug bound to plasma proteins. A Centricon filter (Amicon) was used for concentrated plasma pro t e i n s . SPE was used for plasma, urine, and plasma protein purification, and the results were not appropriated in the case of whole blood samples. Because of the composition of such samples, the cartridges did not allow flow or elution. Liquid-liquid extraction was appropriate in this case.
In order to obtain an adequate separation of prednisone, pre dnisolone, and betamethasone and other endogenous matrix components, it was very important to maintain the room temperature between 15°C to 20°C. The retention times were 8, 11, and 14 min for prednisone, betamethasone, and prednisolone, re s p e c t i v e l y. P recision and accuracy for prednisolone were comparable with other HPLC methods previously described in the literature. The LOQ for prednisolone (100 ng/mL) was higher than in other described methods (5-7). The precision and accuracy at the LOQ, the CV and mean RE were lower than 20%, as recommended in the literature (12) This method is suitable for pharm a c o k i n e t i c study purposes and, specifically, in high-altitude p h a rmacokinetic experiments, in which it is i m p o rtant to assay the drug in whole blood and other biological fluids. Figures 2 and 3 show the concentration-time curves (plasma and whole blood and urinary excretion, respectively) after a single oral dose of 80 mg of pre d n i s o l o n e ( P relone) is given to a healthy volunteer. The maximum and minimal concentrations of pre dnisolone were reached at 2 and 24 h, re s p e c t i v e l y. H o w e v e r, the prednisone concentration found in this study was 20% of the concentration of pre dnisolone. There f o re, prednisone concentration in whole blood was close to the LOQ or undetectable. This pre d n i s o l o n e -p rednisone relationship concentration has also been re p o rted by others (4).
